Nandrolone Phenpropionate

Summary

Nandrolone Phenpropionate (CHEMBL1200412) is an approved small-molecule anabolic agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 406.6 Da · C27H34O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200412
Name	Nandrolone Phenpropionate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	229455
ChEBI	CHEBI:7468
Molecular formula	C27H34O3
Molecular weight	406.6
InChIKey	UBWXUGDQUBIEIZ-QNTYDACNSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CC[C@H]35

IUPAC name: [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate

Pharmacological roles (ChEBI): anabolic agent, androgen.

Also known as: Durabolin, Nandrolone phenpropionate, Nandrolone phenylpropionate, NSC-23162, NANDROLONE PHENPROPIONATE, SID144206893, SID170465193

Patent coverage: 16,783 distinct patent families (53,317 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).